From $10.40 to $8.20. BAL is investment grade for shorters.
Risks to holders (becoming more probable by the day):
- shocker for FY19, missing guidance after atrocious Q3
- SAMR application delays increase chances of it being declined
- FY20 sales soft again with SAMR in the air
- FY21 guidance reduces from $500m sales
- market share decline, especially due to A2M's success.
